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ABSTRACT 
Background: Preclinical results showing therapeutic effect and low toxicity of metronomic 
chemotherapy (MCT) with cyclophosphamide (Cy) + celecoxib (Cel) for mammary tumors, 
encouraged its translation to the clinic for treating advanced breast cancer patients (ABCP). 
Patients and methods: Study design: Single arm, mono-institutional, nonrandomized, phase 
II, two steps clinical trial (Approved by Bioethics Committee and Argentine Regulatory 
Authority). Treatment plan: Cy (50 mg po.d) + Cel (200 mg p.o.bid). Patient eligibility 
criteria: ABCP progressed to anthracyclines, taxanes and capecitabine, ≤4 chemotherapy 
schemes, with good performance status. Biomarkers assessment: Several pro- and anti-
angiogenic molecules and cells were determined as biomarkers. Informed consent signed. 
Primary endpoint: clinical benefit (CB). 
Results: Twenty patients were enrolled. Main clinical outcomes were prolonged disease 
stabilization and partial remission in 10/20 and 1/20 patients, respectively. CB=55%, Time 
to Progression (TTP) =21.1 weeks. Median TTP in patients who achieved CB=35.6 weeks, 
mean Overall Survival=44.20 weeks. There were no grade 3/4 toxicities associated to 
treatment. Circulating endothelial cells (CECs) increased at the time of progression in 
patients who showed CB (P=0.014). Baseline CECs and Circulating Endothelial Progenitor 
cells showed marginal associations with TTP. Serum VEGF decreased (P=0.050), 
sVEGFR-2 increased (P=0.005) and VEGF/sVEGFR-2 ratio decreased, during treatment 
(P=0.041); baseline VEGF and VEGF/sVEGFR-2 were associated with TTP (P=0.035 and 
P=0.030, respectively), while sVEGFR-2 did not.  
Conclusions: Treatment was effective, showed low toxicity profile and excellent 
tolerability. The combination had anti-angiogenic effect. Increased levels of CEC could be 
useful for detecting progression. Baseline VEGF and VEGF/sVEGFR-2 values could be 
useful as early predictors of response. 
Trial registration: ANMAT#4596/09 
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INTRODUCTION  
In advanced breast cancer (ABC), once the first line of treatment has failed, either the 
response rates or the clinical benefits decrease with the subsequent treatments [1]. 
Moreover, even after all the advances made in new treatments, the prognosis of this kind of 
patients continues to be poor [2]. 
Metronomic chemotherapy (MCT) poses a new paradigm in cancer therapy: “less is more 
when administered chronically” [3]. The antitumor effect is achieved through an 
antiangiogenic mechanism demonstrated in pre-clinical and clinical studies, which showed 
a decrease in serum vascular endothelial growth factor (VEGF) [4,5], an increase in serum 
thrombospondin-1 (TSP-1) [6] and serum soluble VEGF receptor 2 (sVEGFR-2) [7], or the 
inhibition of both, local and circulating endothelial cells (CECs) and circulating endothelial 
progenitor cells (CEPs) [8]. Also, other mechanisms of action were described like 
restoration of the immune response [9,10], disruption of cancer stem cells niche [11] or 
abolishment of host pro-tumorigenic and pro-metastatic effects found on standard 
chemotherapy [12]. Cyclophosphamide (Cy), is one of the most used drugs in cancer 
treatment and is one of the earliest cytotoxic drugs used in MCT [13]. Celecoxib (Cel), a 
selective Cyclooxygenase 2 inhibitor, has shown antitumor activity for breast cancer cell 
lines, not only in-vitro but also in-vivo[14], and its use has been translated to the clinic 
[15]. 
This study evaluates the toxicity, tolerability and clinical effect of MCT with Cy and Cel in 
ABC patients, which progressed after standard chemotherapy, and the potential role as 
predictors of response of several pro- and anti-angiogenic molecules and cells. 
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PATIENTS AND METHODS  
Eligibility  
Patients were required to have histopathologically confirmed ABC progressing after no 
more than four lines of chemotherapy. Other inclusion criteria were: acceptable bone 
marrow, renal and liver function, normal calcemia, at least one lesion according to RECIST 
criteria and more than 3 months of life expectancy. Also all patients must be recovered 
from any prior cancer treatment before their inclusion. Signed informed consent was 
obtained from all patients. The complete inclusion and exclusion criteria can be seen in 
supplementary material 1. The protocol was approved by institutional bioethics committee 
and by A.N.M.A.T. (Argentine Regulatory Agency, #4596/09). 
Treatment plan and follow-up 
All patients received Cy 50 mg p.o. daily, plus Cel 400 mg (200 mg p.o. bid).  
Baseline evaluation includes history-taking, physical examination, chest X-ray, abdominal 
and pelvic ultrasound or CT scan and complete biochemical and hematological tests. 
Patients’ follow-up was performed every 14 days during the first 6 months, and every 
28 days thereafter, and consisted of physical examination and hematologic tests. Toxicity 
and response were evaluated every two months or earlier, if it was necessary. Patients were 
followed until progression or death. All the adverse events (AE) were recorded, assessed 
according to Common Terminology Criteria for Adverse Events (CTCAE) v4.03 and 
followed until their resolution. 
Study design and end points  
For this prospective, mono-institutional, single arm, nonrandomized, Phase II Clinical 
Trial, sample size calculation was based on an optimal two-stage minimax design [16]. 
Assuming an alpha error of 0.05 and beta error of 0.20, it was required to recruit a total of 
20 patients, 15 in the first stage and 5 in the second. 
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The primary end point was clinical benefit (CB), which was defined as complete response 
(CR) + partial response (PR) + prolonged stable disease (pSD) ≥24 weeks. Response was 
assessed every two months by RECIST. Time to progression (TTP) was defined as 
the time from the beginning of treatment to time of disease progression (PD). Progression 
free survival (PFS), response rate (RR) and overall survival (OS) were also calculated.  
Biomarker assessments 
Samples were collected at baseline, at the first three visits, and every 2 months thereafter. 
Cellular biomarkers 
Quantification of CECs and CEPs by flow cytometry was carried out on peripheral blood 
collected in tubes with EDTA and separated by Ficoll-Hypaque gradient. Anti-CD45-FITC 
(BD Pharmingen, USA) were used to exclude hematopoietic cells, anti-CD31-ALEXA 
Fluor ® 488 (BD Pharmingen) and anti-CD133-PE (Miltenyi Biotec, Germany) were used 
to determine the percentages of CECs and CEPs, respectively. Samples were evaluated 
using a Coulter Epics XL Flow Cytometer.  
Serological biomarkers 
Serum levels of VEGF, fraction C of VEGF (VEGF-C), sVEGFR-2, sVEGFR-3, and TSP-
1 were evaluated by ELISA (Quantikine© ELISA kit, R & D Systems Inc, Minneapolis, 
MN, USA) according to manufacturer instructions. Blood samples were allowed to clot for 
2h. After centrifugation, serum was collected and stored at -20°C until used.  
Statistical analyses 
Variations in cellular and serological biomarkers were analyzed with ANOVA for repeated 
measurements. The association between baseline values of VEGF, sVEGFR-2, sVEGFR-3 
and VEGF/TSP-1, VEGF/sVEGFR-2, VEGF-C/sVEGFR-2 and VEGF-C/sVEGFR-3 ratios 
with TTP was evaluated using Spearman correlation coefficients. A multiple regression 
analysis was used to evaluate the goodness of prediction. To confirm the prediction, the 
50th percentile of the baseline value was set as a cutoff value and PFS curves were 
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calculated. Group-specific survival curves were calculated by Kaplan–Meier test. Also, a 
multivariate logistic regression analysis was carried out to evaluate association of response 
with hormonal receptor status and baseline ECOG status. All statistical tests were one sided 
with significance defined as a P value < 0.05. STATA was used for the analysis (Statacorp. 
Stata Statistical Software: Release 6.0, College Station, TX, USA, 1999), and GraphPad 
Prism® version 3.0 (GraphPad Software, San Diego, CA, USA) was used for the graphics. 
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RESULTS  
Demographic characteristics 
During the period 2008-2013, were included 20 female patients. The median age at 
diagnosis was 45.5 years (range=36-72). All patients had advanced disease, three of them 
since diagnosis, and were heavily pretreated. All patients that were positive for hormone 
receptors or Her2/neu had previously received hormonal therapy and trastuzumab. 
Demographic characteristics of patients and tumors are summarized in Table 1. 
Adverse events and toxicity 
The hematologic AE associated with treatment were mild: Anemia G2 (N=9/20), 
leukopenia G1 (N=2/20) and G2 (N=2/20), neutropenia G1 (N=1/20) and G2 (N=2/20) and 
thrombocytopenia G2 (N=1/20). Those events were easily overcome with transitory 
reduction of Cy doses. Minimal gastrointestinal toxicity (dyspepsia) G1 was seen in 4/20 
patients, without affecting compliance and was easily reversed by administration of daily 
omeprazole 20 mg v.o. There was no evidence of hepatic, renal or cardiac toxicities 
associated with therapy. All the AE, whether related or not to the therapy, are summarized 
in Table 2. 
Therapeutic response 
The main responses were PR and pSD. PR was observed in 1 patient (RR=5%), while no 
complete responses (CR) were seen. Stable disease was observed in 14/20 patients (70%) 
and pSD in 10/20 patients (50%). Five patients showed progressive disease (PD). The RR 
was 5% (CR+PR=1/20) and the CB 55% (11/20). The therapeutic response is summarized 
in Table 3. 
Mean TTP was 21.1 weeks (median=15.5; range=3-81) and among patients with pSD was 
35.6 weeks (median=27; range=24-81). PFS at 24 weeks was 30%. The OS rate, 1 year 
after enrollment in the trial, was 25% and the mean OS 44.20 weeks (median=36; range=5-
153). Significant longer OS (P=0.0134) was seen in patients with CB (Figure 1). 
Cellular biomarkers 
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The percentages of CECs and CEPs did not show a defined trend during treatment. 
However, CECs showed a significant increase (P=0.010) in patients with CB by the time of 
PD. (Supplementary material 2) 
Serum biomarkers  
Serum concentration of VEGF decreased (P=0.050) and sVEGFR-2 increased (P=0.005) 
during treatment, whereas non-significant variations were detected for VEGF-C, sVEGFR-
3 and TSP-1. The VEGF/sVEGFR-2 ratio decreased significantly during treatment 
(P=0.041). On the other hand, non-significant variations for VEGF/TSP‑ 1, 
VEGF‑C/sVEGFR‑ 2 and VEGF-C/sVEGFR‑ 3 ratios were observed, (Figure 2). 
Predictors of response and Survival analysis 
Each marker that showed significant variation during treatment was correlated with TTP. A 
significant association between baseline VEGF (P=0.011; Figure 3A), baseline 
VEGF/sVEGFR-2 (P=0.029; Figure 3C) and TTP was found. That was not the case for 
sVEGFR-2 Figure 3B). Association between baseline CECs and TTP was marginally 
significant (P=0.075; Figure 3D). When considering VEGF and VEGF/sVEGFR-2 in a 
multiple regression analysis, the goodness of the prediction was not improved (data not 
shown).  
To confirm baseline VEGF and VEGF/sVEGFR-2 ratio as predictors of response, the 50th 
percentile of each biomarker was set as a cutoff value to analyze the percentage of PFS. 
Patients who showed VEGF or VEGF/sVEGFR-2 values equal or lower than the cutoff 
were those who had longer TTP (P=0.0001 Figure 3E; P=0.014, Figure 3F).  
In the multivariate analysis, the chance of pSD or PR was not associated with hormone 
receptor, HER-2/neu or baseline Performance Status ≤2. Finally, when analyzed together 
the three variables, they were not associated with treatment response. 
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DISCUSSION 
The introduction of MCT in the field of cancer treatment has yielded the valuable outcome 
of overcoming drug resistance through the activation of several antitumor mechanisms. 
Moreover, together with the importance of obtaining CB, MCT offers economic benefits 
related to the reduced costs of low doses of already approved drugs, frequently off patent, 
and with low toxicity, avoiding the need of additional treatments and hospitalizations [17]. 
Our pre-clinical results with mammary tumors, treated metronomically with Cy+Cel or 
Cy+Doxorubicin, showing therapeutic effect and low toxicity [18,19] suggested its 
translation to the clinic. 
The AE were scarce and mild and, mainly, hematological. They were associated to chronic 
use of Cy, appeared after several weeks of medication and reverted with dose reduction. 
These type of AE are also the most frequently observed in MCT schemes using Cy [20,21]. 
Dyspepsia was the only non-hematological AE associated to the chronic use of Cel and 
reversed with symptomatic treatment.  
The RR obtained in this study was 5%, which is low compared with those obtained with 
schemes combining Cy+metotrexate±trastuzumab [4,22]. However, since our patients were 
metastatic and heavily pretreated, it is not expected to obtain a high RR. Interestingly, CB 
was close to 60%, which is similar to those reached with high-dose chemotherapy for 
metastatic breast cancer [23,24] but with the advantage of avoiding toxicity. The CB is the 
most frequent outcome found in MCT schemes [25,21,26]. Since disease at this stage is not 
curable, preserving quality of life remains as one of the main goals.  
Mean TTP in this study was 21.1 weeks, and 35.6 weeks for patients who achieved CB. 
Similar results were found by other authors [4,27,22]. Also, the OS was longer in those 
patients with CB. However, two studies reported longer OS using metronomic Capecitabine 
for advanced disease, both with excellent outcomes [28,29].  
Hematopoietic cells and bone marrow-derived CEPs are required for tumor angiogenesis. 
Both, CECs and CEPs, were proposed to be direct targets of MCT [8] and have been 
extensively studied as prognostic and predictive biomarkers in clinical trials using 
10 
 
antiangiogenic agents and MCT, but the results have indicated high inconsistency[30,31]. 
In our study, variations of CECs and CEPs did not show a clear trend but, interestingly, 
patients who showed CB evinced an increase in CECs level at the time of PD, suggesting 
its use as a potential biomarker for follow up. However, some of the limitations in the use 
of CECs as biomarkers are their low concentration in blood and the heterogeneity in the 
methods used to detect them, making their quantification not accurate or comparable. The 
importance of VEGF and its receptors has been extensively reviewed [32-35]. As expected, 
MCT with Cy+Cel reduced VEGF and increased sVEGFR-2 levels, demonstrating its 
antiangiogenic mechanism of action. The decrease in VEGF has also been reported in other 
MCT studies [36,4,5]. However, its usefulness as a predictive biomarker of response has 
not been proved yet and remains controversial [31]. 
No significant changes in serum concentrations of VEGF-C and sVEGFR-3 were found 
during treatment, suggesting that it would not affect lymphangiogenesis.  
TSP-1 inhibits proliferation, growth, motility and adhesion of tumor endothelial cells, and 
its expression may be involved in the regulation of tumor angiogenesis [6]. Our results 
showed that serum TSP-1 was not related to response or PD. Indeed, other clinical MCT 
trials evaluated TSP-1 levels without finding a consistent behavior. Hence, it does not 
seems to be a useful biomarker, at least for MCT treatments [37-40]. 
The association of baseline VEGF and VEGF/sVEGFR-2 ratio with TTP was significant, 
and patients with values below both 50th percentiles, showed higher TTP, suggesting them 
as potential candidates for predictor biomarkers of response to MCT. Interestingly, baseline 
serum VEGF was a better predictor than VEGF/sVEGFR-2 ratio. However, larger studies 
are needed for establishing their utility. As previously proposed[7], it would be interesting 
that those groups that have worked, or are presently working, in MCT trials determine 
baseline VEGF and sVEGFR-2, calculate the ratio and analyze its association with 
therapeutic response.  
In summary, MCT combining Cy+Cel showed low toxicity and CB as main outcome. The 
decrease of VEGF and the increase of sVEGFR-2 confirmed the anti-angiogenic effect of 
the scheme. Also, potential predictive biomarkers of response (baseline VEGF and 
VEGF/sVEGFR-2) and follow-up (CECs) were identified. The need for finding 
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noninvasive biomarkers to predict response to cancer therapies has not yet been fulfilled. 
Hence, we believe that the results herein described may help to achieve such a goal. 
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FIGURES TITLES LEGENDS 
Figure 1. Title: Progression Free Survival and Overall Survival. Legend: A) PFS: 
Progression Free Survival (N=20); mean: 21.1 weeks (median: 15.5, range: 3-81). B) OS: 
Overall Survival (N=20); mean: 44.20 weeks (median: 36, range: 5.14-232.14). C) Overall 
Survival stratified by Clinical Benefit; with CB: median, 45 weeks; without CB: 21 weeks, 
P=0.0134 (Log-rank, Mantel-Cox). 
Figure 2. Title: Variations of serum markers and constructed ratios during treatment. 
Legend: A) VEGF (N= 20): P= 0.050; B) VEGF-C (N=15*): P= 0.128; C) sVEGFR-2 
(N=20): P= 0.005; D) sVEGFR-3 (N=15*): P= 0.128; E) TSP-1 (N=15*): P= 0.369. F) 
VEGF/sVEGFR-2 (N=20): P= 0.041; G) VEGF/TSP-1 (N=15*): P= 0.803; H) VEGF-
C/sVEGFR-2 (N=15*): P=0.293. I) VEGF-C/sVEGFR-3 (N=15*): P= 0.177 (ANOVA for 
repeated measurements).      * Patients included in the first stage. 
Figure 3: Title: Association between biomarkers baseline values and time to progression 
and survival analysis. Legend: A) Baseline VEGF (N=20): r=-0.5055, P=0.011; B) Baseline 
sVEGFR‑2 (N=20): r=0.271, P=0.162; C) Baseline VEGF/sVEGFR‑2 (N=20): r=-0.451, P=0.029; 
(Spearman correlation). D) Baseline CEC (N=20): r=0.364, P=0.075; E) VEGF (N=20), median 
survival= 23 and 7 weeks, P=0.0001. F) VEGF/sVEGFR-2 (N=20), median survival= 26 and 11 
weeks, P=0,014. Kaplan–Meier and Log-rank Test.  PFS: Progression-free Survival. 
TABLES TITLES AND LEGENDS 
Table 1. Title: Demographic characteristics. Legend: 1ER: Estrogen Receptors 2PgR: 
Progesterone Receptors. 
Table 2. Title: Adverse events. Legend: N= 20; *: Associated to treatment; CPK: Creatine 
Phosphokinase; AP: Alcaline Phosphatase; there was no evidence of grade IV toxicity. 
Table 3. Title: Therapeutic response. Legend: Prolonged Stable Disease: ≥24 weeks; Stable 
Disease :> 8 weeks; Response Rate (CR + PR / n) 100; Clinical Benefit (CR + PR + SD> 
24 weeks / n) 100 
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SUPPLEMENTARY MATERIALS TITLES AND LEGENDS 
Supplementary material 1. Title: Inclusion and exclusion criteria. 
Supplementary material 2. Title: CECs and CEPs percentages per patient during 
treatment. Legend: A) CECs:  N = 20, P= 0.286; B) CEPs:  N= 20, P= 0.195. CECs and 
CEPs percentages stratified by presence of Clinical Benefit (CB): C) CECs:  N=11, P= 
0.010; E) CEPs:  N=11, P=0.445; or Absence of CB: D) CECs:  N=9, P=0.887; F) CEPs:  
N=9, P=0.364 (ANOVA for repeated measurements). 
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Table 1. Demographic characteristics  
Age (median & range)  
At diagnosis 45.5 (36-72) 
At the beginning of MCT 57 (38-78) 
Menopausal Status 
Premenopausal 1 
Postmenopausal 19 
Metastases Location 
Bone 12 
Lung 11 
Liver 10 
Skin/Soft tissue 6 
Brain 4 
Others 4 
Number of Metastases  
1 3 
2 9 
>2 8 
Previous Treatment 
Surgery  19 
Radiotherapy 17 
Number of Previous Chemotherapy Lines 
3 13 
4 7 
ECOG Performance Status  
1 7 
2 10 
3 3 
Histology  
      Ductal carcinoma 14 
      Lobular carcinoma 3 
      Paget disease 1 
      Others 2 
ER Status1 
Positive  13 
Negative 7 
PgR Status2 
Positive 9 
Negative 11 
Her2/Neu Status 
Positive 7 
Negative 10 
Unknown 3 
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TABLE 2. ADVERSE EVENTS AND EVOLUTION OF HEMATOLOGIC AND 
SEROLOGICAL PARAMETERS 
 
Adverse Events 
 
Grade  
0 1 2 3 
n % n % n % n % 
Hematologic         
Anemia 7 35 3 15 9* 45 1 5 
Leukopenia 14 70 2
* 10 2
* 10 2 10 
Neutropenia 16 80 1* 5 2* 10 1 5 
Thrombocytopenia 19 95   1* 5   
Non-hematologic         
Transaminasemia 18 90 1 5 1 5   
Elevated AP 14 70 2 10 4 20   
Elevated CPK 17 85 1 5 2 10   
Dyspepsia 15 75 4* 20 1 5   
Diarrhea 16 80 3 15 1 5   
Nauseas 15 75 3 15 2 10   
Vomits 18 90 2 10     
Anorexia 15 75 4 20   1 5 
Weight Loss 19 95 1 5     
Asthenia 12 60 1 5 1 5   
Urticaria 19 95 1 5     
Dyspnea 11 55 5 25 3 15 1 5 
Hypertension 17 85 2 10 1    
Edema 19 95 1 5     
Cough 14 70 4 20 2 10   
Fever 19 95 1 5     
Ascites 17 85 1 5 1 5 1 5 
Pleural Effusion 17 85 2 10 1 5   
Pruritus 17 85 3 15     
Abdominal Pain 19 95   1 5   
Muscular Pain 16 80 3 15 1 5   
Arthralgia-bone pain 11 55 5 25 3 15 1 5 
Alopecia 18 90 1 5 1 5   
Lymphatic Edema 15 75 2 10 3 15   
Depression 14 70 5 25 1 5   
Headache 18 90 2 10     
Dysuria 18 90 1 5     
Neuralgia 18 90 2 10     
23 
 
TABLE 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
Therapeutic response 
 
n=20 
n % 
Complete Remission  0 0 
Partial Remission 1 5 
Stable Disease 14 70 
Prolonged Stable Disease 10 50 
Disease Progression 5 25 
Response Rate 5% 
Clinical Benefit 55% 
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SUPPLEMENTARY MATERIAL 
SUPPLEMENTARY MATERIAL 1. INCLUSION AND EXCLUSION CRITERIA 
INCLUSION CRITERIA EXCLUSION CRITERIA  
 Aged between 18 and 80 years. 
 More than 3 months of life expectancy. 
 Histologically or cytologically confirmed advanced 
breast cancer. 
 Patients with advanced breast cancer with 
objective evidence of recurrence or progression of 
illness, which are not considered for curative 
treatment and had received, at least, 
anthracyclines, taxanes and capecitabine in 
advanced illness and/or in adjuvancy. 
 No more than four chemotherapy schemes, 
including adjuvancy and neo-adjuvancy.  
 Patients with, at least, one measurable lesion 
according to RECIST (Response Evaluation Criteria 
in Solid Tumors) criteria.  
 ECOG (Eastern Cooperative Oncologic Group) 
Performance Status ≤3.  
 Adequate bone marrow function (white blood cells 
> 4000/mm3 and platelets > 100.000/mm3).  
 Adequate renal function (urea <0.45 g/l and 
creatinine clearance 60 mg/l). 
 Adequate hepatic function (total bilirubin <10 mg/l 
and SGOT <19 U/l).  
 Calcemia within normal limits (8.5- 10.5 mg/dl). 
 Signed informed consent. 
  
 
 
 Aged  <18 or >80 years. 
 Extensive radiotherapy within the four previous 
weeks (≥30% of bones with bone marrow, i.e. 
complete pelvis or half vertebral column). 
Strontium-90 (or other radiopharmaceutical) 
within the previous three months. 
 Present or previous systemic oncologic illness, 
active within the three previous years to the 
inclusion (apart from breast cancer, or in-situ 
cervical cancer adequately treated, uterus or skin 
squamous cell carcinoma). 
 Laboratory results:  
o Platelets < 100 x 109/l. 
o International Normalized Ratio (INR) > 1.6. 
o Total bilirubin >1.5 normal value superior limit 
(NVSL). 
o Alanine aminotransferase (ALT/SGPT) o aspartate 
aminotransferase (AST/SGOT) >2.5 NVSL, without 
demonstrable hepatic metastases, or >5 NVSL in 
the presence of hepatic metastases. No more than 
three repeated tests within the screening period. 
 Risk (in the opinion of the investigator) of 
transmission of HIV, or B or C hepatitis viruses, by 
blood or other body fluids.  
 Treatment with a non-approved/experimental drug 
within the four weeks previous to the inclusion in 
the study.  
 Any concomitant severe illness that makes not 
convenient for the patient to participate in the 
study or that prevent compliance to the trial 
protocol, i.e.:  severe renal or hepatic insufficiency, 
or unstable/non-compensated respiratory or 
cardiac conditions. 
 Known allergy to Cel, Cy or their components, 
allergy to sulfa drugs; intolerance to aspirine, 
asthma or nasal poliposis.  
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SUPPLEMENTARY MATERIAL 2. CECS AND CEPS PERCENTAGES PER PATIENT DURING TREATMENT AND 
STRATIFIED BY PRESENCE OR ABSENCE OF CLINICAL BENEFIT 
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